MET and thyroid cancer: MET is a member of the surface transmembrane receptor family expressed in both normal and malignant epithelial and endothelial cells, as well as in neural cells, hematopoietic cells, and hepatocytes.254,255 Overexpression of MET has been found in various carcinomas, such as hepatocellular carcinoma, lung cancer, breast cancer, thyroid cancer, kidney cancer, gastric cancer, and CRC.256–262 Increased mRNA and protein levels of MET were reported in CRC tissues, and its connection to tumor progression and metastasis was demonstrated in several studies.263–265